GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

Alembic Pharmaceuticals has acquired UTILITY therapeutics, expanding its portfolio with the addition of Pivya to treat uUTIs.

While the UK continues its close 25-year partnership with Gavi, the US is halting funding to the organisation. In a move that ...

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.

AbbVie gains control of an in vivo CAR-T therapy that could overcome limitations with currently approved autologous ...

Scientific experts are concerned about what role vaccines will play in US public health strategy under the Trump ...

Sanofi's antibody riliprubart has received orphan drug designation from Japan's MHLW for its potential to treat CIDP.

Price differences are especially pertinent with these weight loss drugs, which are officially called glucagon-like peptide-1 ...

Proposals for drug exclusivities and feeble measures to combat drug shortages are unlikely to boost innovation, say some ...

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.